Invitrogen Licenses Amplification Patents to Qiagen and Others | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen today said that it had non-exclusively licensed its patents covering the random prime amplification of nucleic acids to Qiagen, New England Biolabs, and Kirkegaard & Perry Laboratories.
 
The patents cover methods and kits used for “substantially” amplifying nucleic acids, Invitrogen said. The technology is used in common lab techniques, such as random prime labeling reactions, first-strand cDNA synthesis, and whole genome amplification.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.